ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
ALX Oncology Holdings (Nasdaq: ALXO) has appointed Alan Sandler, M.D. as Chief Medical Officer. Dr. Sandler brings over 30 years of experience in oncology and drug development, having previously served as Executive Vice President and CMO at Mirati Therapeutics, President and Global Head of Development in Oncology at Zai Lab, and Senior Vice President at Genentech. He will lead the clinical development of evorpacept, the company's investigational lead compound, into late-stage clinical trials. Dr. Sandler, who previously served on ALX Oncology's Board of Directors, has co-authored over 300 publications and holds an M.D. from Rush Medical College.
ALX Oncology Holdings (Nasdaq: ALXO) ha nominato Alan Sandler, M.D. come Chief Medical Officer. Il Dr. Sandler porta con sé oltre 30 anni di esperienza in oncologia e sviluppo di farmaci, avendo precedentemente ricoperto il ruolo di Executive Vice President e CMO presso Mirati Therapeutics, Presidente e Responsabile Globale dello Sviluppo in Oncologia presso Zai Lab, e Senior Vice President presso Genentech. Dirigerà lo sviluppo clinico di evorpacept, il principale composto investigativo dell'azienda, verso studi clinici di fase avanzata. Il Dr. Sandler, che ha precedentemente fatto parte del Consiglio di Amministrazione di ALX Oncology, è co-autore di oltre 300 pubblicazioni e possiede un M.D. dal Rush Medical College.
ALX Oncology Holdings (Nasdaq: ALXO) ha nombrado a Alan Sandler, M.D. como Director Médico. El Dr. Sandler aporta más de 30 años de experiencia en oncología y desarrollo de medicamentos, habiendo ocupado anteriormente el cargo de Vicepresidente Ejecutivo y CMO en Mirati Therapeutics, Presidente y Jefe Global de Desarrollo en Oncología en Zai Lab, y Vicepresidente Senior en Genentech. Dirigirá el desarrollo clínico de evorpacept, el principal compuesto investigacional de la empresa, hacia ensayos clínicos en etapas avanzadas. El Dr. Sandler, quien anteriormente sirvió en la Junta Directiva de ALX Oncology, ha coautorado más de 300 publicaciones y posee un M.D. del Rush Medical College.
ALX Oncology Holdings (Nasdaq: ALXO)는 Alan Sandler, M.D.를 최고 의학 책임자로 임명했습니다. Sandler 박사는 항암 및 약물 개발 분야에서 30년 이상의 경력을 가지고 있으며, 이전에 Mirati Therapeutics에서 수석 부사장 및 CMO, Zai Lab에서 항암 개발의 글로벌 H을 제정하였고, Genentech에서 수석 부사장으로 재직했습니다. 그는 회사의 주요 연구 화합물인 evorpacept의 임상 개발을 고위 단계 임상 시험으로 이끌 것입니다. Sandler 박사는 ALX Oncology의 이사회에서 이전에 일했으며, 300편 이상의 공동 저자를 가지고 있으며 Rush Medical College에서 의학 박사(M.D.)를 취득하였습니다.
ALX Oncology Holdings (Nasdaq: ALXO) a nommé Alan Sandler, M.D. au poste de Directeur Médical. Dr. Sandler possède plus de 30 ans d'expérience en oncologie et en développement de médicaments, ayant précédemment été Vice-Président Exécutif et CMO chez Mirati Therapeutics, Président et Responsable Global du Développement en Oncologie chez Zai Lab, et Vice-Président Senior chez Genentech. Il dirigera le développement clinique de evorpacept, le principal composé investigational de l'entreprise, vers des essais cliniques avancés. Dr. Sandler, qui a auparavant siégé au Conseil d'Administration d'ALX Oncology, a coécrit plus de 300 publications et est titulaire d'un M.D. du Rush Medical College.
ALX Oncology Holdings (Nasdaq: ALXO) hat Alan Sandler, M.D. zum Chief Medical Officer ernannt. Dr. Sandler bringt über 30 Jahre Erfahrung in der Onkologie und der Arzneimittelentwicklung mit, nachdem er zuvor als Executive Vice President und CMO bei Mirati Therapeutics tätig war, Präsident und Global Head of Development in Oncology bei Zai Lab sowie Senior Vice President bei Genentech. Er wird die klinische Entwicklung des evorpacept, des führenden Forschungsprojekts des Unternehmens, in späte klinische Studien leiten. Dr. Sandler, der zuvor im Vorstand von ALX Oncology tätig war, hat über 300 Publikationen co-autorschaft und hat einen M.D. vom Rush Medical College.
- Appointment of highly experienced CMO with 30+ years in oncology and drug development
- New CMO brings prior knowledge of company operations from Board position
- Strong expertise in clinical development and regulatory affairs for late-stage trials
- None.
Dr. Sandler brings more than 30 years of experience as a distinguished leader in oncology and drug development
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives, announced today the appointment of Alan Sandler, M.D., as Chief Medical Officer.
“Dr. Sandler’s breadth of experience and demonstrated leadership capabilities across oncology and drug development, as well as his in-depth knowledge of ALX Oncology while he was a member of our Board, will be instrumental in helping us achieve our near- and longer-term objectives,” said Jason Lettmann, Chief Executive Officer at ALX Oncology. “He is the ideal leader to advance the clinical development of evorpacept, our investigational lead compound, into late-stage clinical trials. We are thrilled to have him join our accomplished leadership team as we look towards 2025, which will be a transformational year for the company.”
Dr. Sandler’s expertise spans clinical development and operations, regulatory affairs, drug safety and development strategies. He previously held the position of Executive Vice President, Chief Medical Officer at Mirati Therapeutics, prior to its acquisition by Bristol Myers Squibb in early 2024. Before joining Mirati, Dr. Sandler was the President, Global Head of Development in Oncology at Zai Lab. Prior to that, he held roles of increasing responsibility at Genentech, a member of the Roche Group, where he ultimately served as Senior Vice President and Global Head, Product Development of Oncology Solid Tumors. Dr. Sandler’s academic positions include roles at Oregon Health and Science University, where he served as Professor of Medicine and Head of the Division of Hematology/Medical Oncology and Medical Lead of the Thoracic Oncology Program; Vanderbilt University as an Associate Professor of Medicine and Indiana University as Assistant Professor of Medicine.
“While I served as a member of ALX Oncology’s Board of Directors, I had the opportunity to observe firsthand both the company’s exceptional leadership team and the impressive clinical activity of evorpacept as an immuno-oncology agent capable of enhancing the efficacy of current and future cancer therapies,” said Dr. Sandler. “In my new role, I look forward to continuing the development of this investigational therapy with the vision to improve patient outcomes in a wide range of tumor types and treatment settings.”
Dr. Sandler earned his M.D. from Rush Medical College and completed his training in internal medicine and fellowship in medical oncology at Yale-New Haven Medical Center. He has co-authored over 300 publications, including peer-reviewed articles, reviews, abstracts, and book chapters.
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology’s filings with the Securities and Exchange Commission (“SEC”), including ALX Oncology’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
FAQ
Who is the new Chief Medical Officer of ALX Oncology (ALXO)?
What is Dr. Alan Sandler's experience before joining ALX Oncology (ALXO)?
What will be Dr. Sandler's main responsibility at ALX Oncology (ALXO)?
